First Page | Document Content | |
---|---|---|
Pharmaceutical sciences Clinical pharmacology Pharmacology Therapeutics United States Public Health Service Center for Drug Evaluation and Research Perelman School of Medicine at the University of Pennsylvania National Institutes of Health Genomic Medicine Institute Medicine Health Food and Drug Administration | ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)Add to Reading ListSource URL: www.fda.gov.Download Document from Source WebsiteFile Size: 26,35 KBShare Document on Facebook |
CENTER FOR DRUG EVALUATION AND RESEARCH DRUG SAFETY PRIORITIES 2017DocID: 1ueGS - View Document | |
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208573Orig1s000 SUMMARY REVIEWDocID: 1t19G - View Document | |
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022526Orig1s000 SUMMARY REVIEWDocID: 1sZi5 - View Document | |
MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCHDocID: 1sPXO - View Document | |
Abstract # 2639 Enhanced (Q)SAR Models for Prediction Rodent Carcinogenicity Naomi L. Kruhlak1, Dongyu Guo1, Kevin P. Cross2, Lidiya Stavitskaya1 FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampshire ADocID: 1swgc - View Document |